Renal Potassium Excretion Visualized on 82Rubidium PET/CT

Mads Ryø Jochumsen; Lars Poulsen Tolbod; Michael Borre; Jørgen Frøkiær; Kirsten Bouchelouche; Jens Sörensen

doi:10.1007/s13139-020-00637-8

Renal Potassium Excretion Visualized on ⁸²Rubidium PET/CT

Nucl Med Mol Imaging. 2020 Apr;54(2):120-122. doi: 10.1007/s13139-020-00637-8. Epub 2020 Apr 15.

Authors

Mads Ryø Jochumsen^{1

2}, Lars Poulsen Tolbod^{1

2}, Michael Borre^{2

3}, Jørgen Frøkiær^{1

2}, Kirsten Bouchelouche^{1

2}, Jens Sörensen^{1

2}

Affiliations

¹ 1Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Palle Juul-Jensens Boulevard 165, 8200 Aarhus N, Denmark.
² 2Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
³ 3Department of Urology, Aarhus University Hospital, Aarhus, Denmark.

Abstract

The positron emission tomography (PET) flow tracer ⁸²Rubidium is a known potassium analogue. During our studies of tumor blood flow in prostate cancer, we found that approximately 10% of the patients had high urinary ⁸²Rubidium activity. In roughly half of these patients, the increased renal rubidium/potassium excretion was either causing hypokalemia or explained by Thiazide treatment. In the other half, there was no obvious explanation or clinical consequence of the renal rubidium/potassium excretion. This is the first time enhanced renal potassium excretion is visualized on ⁸²Rubidium PET/CT.

Keywords: 82Rubidium; Hypokalemia; PET; Potassium; Prostate cancer; Renal excretion.